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Developmental syndromesAbstract The BRAF gene encodes for a serine/threonine protein kinase that participates in the
MAPK/ERK signalling pathway and plays a vital role in cancers and developmental syndromes
(RASopathies). The current review discusses the clinical signiﬁcance of the BRAF gene and other
members of RAS/RAF cascade in human cancers and RAS/MAPK syndromes, and focuses the
molecular basis and clinical genetics of BRAF to better understand its parallel involvement in both
tumourigenesis and RAS/MAPK syndromes––Noonan syndrome, cardio-facio-cutaneous syn-
drome and LEOPARD syndrome.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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The BRAF gene on chromosome 7 (7q34) encodes the BRAF
protein, which participates in the MAP kinase/ERK signalling
pathway. This pathway regulates important cell functions
including cellular growth, differentiation, proliferation, senes-
cence and apoptosis (Peyssonnaux and Eychene, 2001). Differ-
ent variant products of the BRAF gene have been reported as
both activating and silencing the RAS/MAPK pathway
(Rajagopalan et al., 2002; Davies et al., 2002; Makita et al.,
2007; Cho et al., 2006; Aoki and Matsubara, 2013). Addition-
ally, an increase in protein expression or activity can disturb
the Ras–MAPK signalling pathway, which in turn can result
in different developmental disorders such as Noonan
syndrome (NS), cardio-facio-cutaneous (CFC) syndrome,
Costello syndrome, and different types of human cancers.
Similar to BRAF, germline mutations in the PTPN11, SOS1,
RAF, and KRAS genes also inﬂuence the RAS/MAPK signal-
ling pathway and contribute to the development of NS in
approximately 70% of patients (Rodriguez-Viciana et al.,
2006; Tartaglia et al., 2001; Romano et al., 2010).
In addition to germline mutations, BRAF somatic muta-
tions have been reported in Langerhans cell histiocytosis
(Badalian-Very et al., 2010; Satoh et al., 2012), Erdheim–
Chester disease (Haroche et al., 2012), and lung, colon,
thyroid, and melanoma cancers, as well as in non-Hodgkin
lymphoma (Davies et al., 2002; Makita et al., 2007; El-Osta
et al., 2011; Brose et al., 2002; Ohtake et al., 2011; Niihori
et al., 2006). More than 80% mutations in the BRAF gene have
been reported with varied frequencies. For instance, 67% of
melanomas exhibit BRAF mutations, whereas 30% of other
tumours, such as thyroid cancer (15%), lung cancer (3%)
and colorectal cancer (12%), present with BRAF mutations
(Davies et al., 2002; Clancy et al., 2013; Puxeddu and Filetti,
2013). Among all cancers, V600E, has been examined in
66% of malignant melanomas (Rajagopalan et al., 2002;
Ibrahim and Haluska, 2009), and speciﬁcally localised to the
serine/threonine kinase domain. Additionally, somatic muta-
tions resulting in BRAF heterozygous variants in kinase
domain, such as G1382T (R461I), T1385G (I462S), G1388A(G463E), and A1798G (K600E), have been identiﬁed in colo-
rectal cancer patients (Wan et al., 2004). According to some
recent reports of the past 2–3 years, somatically acquired
T1799A (V600E) mutation has been characterised in hairy cell
leukaemia and related lymphoproliferative disorders (Xi et al.,
2012; Blombery et al., 2012). However, the somatic mutations
with G465V (exon 11) and L596R (exon 15) amino acid substi-
tutions have been characterised in human lung adenocarcino-
mas (Naoki et al., 2002). An in-frame fusion of the AKAP9
gene (exons 1–8) to the BRAF gene (exons 9–18), which occurs
through a paracentric inversion of chromosome 7, has been
preferentially recognised in radiation-induced papillary carci-
nomas, compared to BRAF point mutations (Ciampi et al.,
2005). Moreover, two novel BRAF gene fusions––KIAA1549-
BRAF and FAM131B-BRAF––have been identiﬁed in pilocytic
astrocytomas (Cin et al., 2011; Sievert et al., 2009), and one
(PAPSS1-BRAF) in melanoma (Hutchinson et al., 2013).
At the level of the BRAF protein, the amino acid variations
observed as a result of BRAF mutations––R461I, I462S,
G463E, G463V, G465A, G465E, G465V, G468A, G468E,
N580S, E585K, D593V, F594L, G595R, L596V, T598I,
V599D, V599E (V600E), V599K, V599R, V600K, and
A727V––are mostly clustered in two regions: the glycine rich
P loop region and the activation domain––protein kinase
domain (Fig. 1) (Wan et al., 2004). These mutations change
the activation peptide from an active state to an inactive state.
For instance, as has been published previously, the charge den-
sity of the phenyl ring of Phe467 in the P loop interacts with
the aliphatic side chain of vicinal Val599 (Val600). However,
in the case of substitution of the medium-sized hydrophobic
Val with a bulky charged moiety (Glu, Asp, Lys, or Arg), as
is often found in human cancers, the interactions that preserve
the DFG motif in an inactive conformation are destabilised,
hence, the activation segment ﬂips stereochemically into an
inactive position (Wan et al., 2004; Bollag et al., 2012).
Depending on the nature of the mutation, the activity of the
BRAF protein towards MEK/ERK may also vary, thereby
resulting in diversity of the underlying cellular pathways.
The present review summarises the role of the BRAF gene
in different cancers and developmental disorders (NS, CFC
Figure 1 Protein domains connecting the cancers and RASopathies, and 3D structure of the BRAF protein. (A) BRAF mutations
common to kinase domain (457–717 amino acids) are characterised mostly in melanoma, colorectal cancer, lung cancer, thyroid cancer
and ovarian cancer, and CFC. (B) 3D structure of the BRAF protein with highlighted residues at the 241, 257, 469, 499 and 600
positions––the most common sites for amino acid substitutions, screened in NS, CFC and cancer diseases.
Clinical signiﬁcance of the BRAF gene 361and LEOPARD syndromes). For this purpose, different elec-
tronic databases like PubMed, OMIM and UniProt were
searched with the keywords ‘‘BRAF mutation’’, ‘‘BRAF
V600E’’, ‘‘cancer BRAF’’, ‘‘BRAF MEK’’, ‘‘KRAS BRAF’’,
‘‘BRAF NRAS’’, ‘‘BRAF CFC’’, and ‘‘BRAF RASopathies’’
for extensive literature review.
2. BRAF mutations in various types of cancers
Cancer results from mutations in oncogenes (Hussain et al.,
2014; Gao et al., 2014), including BRAF (Fig. 2), that provide
alternative pathways for cellular processes, such as cell prolif-
eration, differentiation and death (Peyssonnaux and Eychene,
2001). Dysregulated binding of RAS to BRAF and MEK pro-
teins in the Ras/Raf/MEK/ERK cascade (Fig. 3A)––as a result
of BRAF mutations––causes spontaneous signalling to down-
stream kinases, resulting in the overactivation of downstream
signalling by MEK and ERK (Peyssonnaux and Eychene,
2001; Namba et al., 2003). In more than 90% of the cases of
BRAF mutations, the thymine residue at the nucleotide posi-
tion 1799 is substituted with an adenine residue (Tan et al.,
2008), and extensively reported in papillary thyroid tumours
(40%) Chappell et al., 2011; Pritchard et al., 2007, melanoma
(<50%) Chappell et al., 2011; Tan et al., 2008; Ascierto et al.,2012, colorectal tumours (10%) Cho et al., 2006, prostate
tumours (10%) Cho et al., 2006 and non-small-cell lung can-
cers (Li et al., 2006; Benlloch et al., 2006; Deng et al., 2004;
Gear et al., 2004; Maldonado et al., 2003; Puxeddu et al.,
2004; Elisei et al., 2008). In addition to this, Gayane et al.
conﬁrmed the occurrence of the BRAF V600E mutation in
Langerhans cell histiocytosis patients (57%) Badalian-Very
et al., 2012. Enrico et al. used parallel sequencing to determine
that the V600E mutation is the most probable cause of hairy
cell leukaemia (Tiacci et al., 2011).
Various BRAF mutations have been observed in 66% of
malignant melanomas, and all of these mutations occurred in
the serine/threonine kinase domain, resulting in the single var-
iant V600E (Davies et al., 2002). Such mutations increase the
kinase activity and transform the mutated protein in NIH3T3
cells (Davies et al., 2002). A few experimental studies have
documented that these mutations are not observed in cancer
cell lines derived from neuroblastomas, leukaemias, and
lymphomas, or pancreatic, prostate, bladder, testicular, renal
and cervical carcinomas (Davies et al., 2002; Vredeveld et al.,
2012).
Because the over-activation of the RAS–RAF signalling by
oncogenic BRAF has been associated with many different
types of malignancies (Brose et al., 2002; Nikiforova et al.,
Figure 2 Venn diagram to show BRAFmutations (amino acid variations), characterised in different cancer types. The highest number of
mutations is seen in melanomas, indicated in blue colour circle. The smaller number of mutations is observed in thyroid cancer, shown in
red colour circle. However, mutations observed in more than one type of cancer are shown in the overlapping regions. For example, the
G469R and V600E mutations are characterised in all 4 types of cancers, shown by the overlapping region.
362 M.R.M. Hussain et al.2003; Wang et al., 2003; Park et al., 2013), it has been sug-
gested that a decrease in the activity of oncogenic BRAF would
be beneﬁcial, thereby making this gene a potential therapeutic
target in oncology (Davies et al., 2002; Nikiforova et al., 2003;
Bhatia et al., 2009).
3. Papillary thyroid cancer (PTC)
BRAF, an isoform of the RAF kinase in the MAPK pathway,
mutations have been reported in a variety of human cancers
(Fig. 2) Brose et al., 2002; Hussain et al., 2012; Benlloch
et al., 2006; Bosmuller et al., 2013; Ul-Haq et al., 2012 includ-
ing papillary thyroid cancer (PTC), which accounts for 80% of
thyroid malignancies (Xing et al., 2005). Papillary thyroid car-
cinomas harbour point mutations in the BRAF and RAS genes
that underlie the MAPK pathway (Fig. 3A) Nikiforov, 2011.
The estimated occurrence of BRAF mutations in PTC patients
ranges from 29% to 83%. Many clinical studies have been con-
ducted to determine the behaviour of such mutations, particu-
larly the most common V600E mutant, in the majority of
sporadic PTC cases (Jo et al., 2006). Additionally, the associ-
ation of the BRAF V600E mutation with the transcription
co-activator Yes-associated protein 1 (YAP1) has recently
been found to be responsible for tumour progression in PTC
and anaplastic thyroid cancer (Lee et al., 2013). Another studyin the same context supports the possible association between
the expression patterns of the PKM2 gene and BRAF muta-
tions that mediate PTC (Feng et al., 2013). According to recent
ﬁndings, the intriguing occurrence of the K601E and V600E
mutations in the BRAF gene has been found in multifocal
papillary thyroid carcinoma (mPTC) and conventional PTC,
respectively (Kim et al., 2013).
Another recent study concerning the conversion of
metastatic papillary thyroid carcinoma (PTC) into primary
squamous cell carcinoma (SCC) has suggested that PTC can
reoccur in the cervical lymph nodes, as reported in an
86-year-old woman 10 years after total thyroidectomy (Lee
et al., 2013). After thyroidectomy, the failure of radioiodine
treatment may cause a recurrence of PTC and increased mor-
bidity and mortality. Hence, the more aggressive behaviour of
the BRAF V600E mutation results in the need for a stronger
treatment for PTC patients to overcome the recurrence of
tumours (Xing et al., 2005). The independent role of the BRAF
V600E mutation as a potential marker in the risk stratiﬁcation
of papillary thyroid cancer (PTC) patients can help to efﬁ-
ciently treat patients and prevent recurrent disease (Xing,
2007). Similar ﬁndings have also indicated a close relationship
between PTCs carrying the V600E mutation and high expres-
sion levels of VEGF (vascular endothelial growth factor),
which in turn is associated with aggressive tumour
Figure 3 Schematic diagram showing the RAS–RAF signalling pathway with different cancers (A) and RASopathies (B). In melanoma,
in red colour, RAS and BRAF mutations activate both effector pathways: Raf–MEK–ERK (BRAF gene) and PI3K–Akt signalling. In
thyroid cancer (papillary carcinoma), in grey colour, both RAS and RAF (BRAF) play a combined critical role in proliferation. Molecular
cascade underlying prostate cancer (turquoise) underlies both MAPK and p53 pathways. The glioma involves PDGF, PDGFR, Sch,
Grb2, SOS, Ras, Raf and MAPK. In colorectal cancer, indicated in blue colour, both TGF-b and MAPK signalling pathways play a
critical role. RAS/RAF signalling transduction for developmental syndromes (NS, CFC and LEOPARD) is indicated in B.
Clinical signiﬁcance of the BRAF gene 363characteristics such as tumour size, extrathyroidal extension
and tumour stage (Nikiforov, 2011). At the protein level,
V600 in the glycine-rich loop of BRAF forms a hydrophobic
interaction with P468, which stabilises the DFG motif by
preventing the phosphoryl transfer to the DFG triad, ﬁnally
locking it in an inactive conformation. As a result of the
V600E variation, the substitution of valine with glutamic acid
disrupts that hydrophobic interaction and induces BRAF
phosphorylation, which is associated with an up to 700-fold
increase in the MEK–ERK signalling (Ziai and Hui, 2012).
Fine-needle aspiration (FNA) of biopsy material (thyroid
nodules) is the most reliable way to preoperatively diagnose
thyroid carcinomas carrying the BRAF V600E mutation. In
the United States, approximately 60–70% of the biopsied
thyroid nodules are characterised as benign, while 4–10% are
categorised cytologically malignant (Adeniran et al., 2011).
The nature of the remaining 20–30% of the nodules cannot
be diagnosed due to cytological uncertainty. In such equivocal
cytological contexts, testing FNA specimens for the BRAF
V600E mutation has facilitated the deﬁnitive diagnosis of
PTC (Adeniran et al., 2011; Rowe et al., 2006).In paediatric PTC, appropriate surgery with adjuvant radi-
oiodine ablation is often enough to cure the disease, even if the
disease is quite extensive. This is because BRAF mutations are
rarely found in paediatric PTC, or these mutations appear to
cause the poor prognosis of PTC. Moreover, a high occurrence
of the T1799A nucleotide mutation, which results in the V600E
mutation (previously known as V599E), in the lymph
node-metastasised PTC tumours, it may reﬂect the de novo
development of thyroid cancer cells of increased malignancy.
In another report concerning the lymph node metastasis of
PTC, a novel mutation––the deletion of codon 601––appeared
to be the cause of the genetic alteration underlying the progres-
sion of PTC cells in the lymph nodes (Vasko et al., 2005).4. BRAF gene and malignant melanoma
According to recent statistics released by the National Cancer
Institute of the NIH (http://www.cancer.gov/cancertopics/
types/melanoma), 76,100 new cases of melanoma have been
reported in 2014. Massachusetts General Hospital documented
Figure 3 (continued)
364 M.R.M. Hussain et al.a male approximately 68 years old who developed metastatic
melanoma to the groin and pelvis 11 years after a melanoma
on his right leg was excised (Sullivan et al., 2013). Addition-
ally, in 2008, the highest (8420) estimated deaths in the United
States were due to metastatic melanoma (Jemal et al., 2008). In
the same year, Wajapeyee et al. (2008) used genomewide RNA
interference screening to identify 17 factors––F-box protein
(FBXO31)––necessary for oncogenic BRAF to regulate senes-
cence in primary ﬁbroblasts and melanocytes.
Dermatologists are typically on the forefront to identify
patients with increased risk of melanoma due to genetic predis-
position; however, most melanoma cases are sporadic and
result from moderate genetic risk factors (Udayakumar
et al., 2010). The strongest genetic risks for melanoma develop-
ment have been observed as a result of genetic variations in the
cyclin-dependent kinase inhibitor 2A (CDKN2A) gene located
on chromosome 9p21 (Nelson and Tsao, 2009). Studies have
also identiﬁed a high frequency of BRAF somatic missense
mutations in malignant melanoma. In addition, MC1R
variants are strongly associated with BRAF mutations in
non-CSD (chronic solar-damaged) melanoma (Fargnoli
et al., 2008). Thus, high risk for melanoma is associated with
the both the MC1R and BRAF genes. However, BRAF muta-
tions have also been rarely detected in CSD melanomas
(18.2%), as well as in acral (15.5%) and mucosal (12.5%) mel-
anomas (Si et al., 1990).
More than 90% of the BRAF mutations in human malig-
nant melanomas involve codon 600, and 80% of these muta-
tions are comprised of the V600E mutation. Nevertheless,
V600K is the second most common mutation, constituting
14–28% of the BRAF mutations that underlie melanoma
(Forschner et al., 2013). From one recent study, three novelmutations in exon 11 of BRAF––G442S, W450Stop and
I457T––have been identiﬁed in melanoma (acral and mucosal)
in addition to the eight previously reported mutations in exon
11 and 15: G466R, D594E, D594G, V600E, V600K, K601E,
W604Stop and S616F (Si et al., 1990).
From the literature, the BRAF protein has three AKT
phosphorylation sites: Thr439, Ser428 and Ser364. In vitro sub-
stitution of the Thr439 residue with an Ala residue leads to
BRAF activation through the loss of AKT-induced inhibition
of RAF1 phosphorylation. Hence, the detection of K438T and
K438Q in melanoma, similar to Thr439, is likely to inhibit
AKT-dependent phosphorylation (Brose et al., 2002). Simi-
larly, the presence of Ser428, Ser364 and the aforementioned
novel mutations (G442S, W450Stop and I457T) (Si et al.,
1990) in the vicinity of Thr439 are suggested to play a role
in tumourigenesis (Brose et al., 2002).5. Involvement of the BRAF and KRAS genes in ovarian cancer
During the past few years, patients with epithelial ovarian
cancer have been treated identically in clinical trials and in
pathological practise (Gershenson, 2013). The development
of a 2-tier system for serous carcinomas, with low and high
grades, is now generally accepted (Kohn and Hurteau, 2013).
This simple approach, which is based on biological evidence,
proposes that both tumours develop through different path-
ways. With infrequent mitotic ﬁgures, low-grade serous carci-
nomas, such as invasive micropapillary serous carcinoma
(MPSC), show low-grade nuclei and are believed to evolve
from adenoﬁbromas or cystadenomas, which are borderline
in the tumour-serous carcinoma sequence, via mutation in
Clinical signiﬁcance of the BRAF gene 365the KRAS, BRAF, or ERBB2 genes (Vang et al., 2009). Muta-
tions in the KRAS, BRAF, or ERBB2 genes result in the upreg-
ulation of MAPK, which in turn regulates uncontrolled
proliferation in atypical proliferative serous tumours (APST).
Serous cystadenomas found adjacent to APSTs have been
found to have identical KRAS or BRAF mutations, suggesting
that the presence of APSTs near the cystadenomas may sup-
port the regulation of serous carcinomas (Vang et al., 2009).
While BRAF V600E has been reported to be prevalent in
33% of tumours in the past, recent ﬁndings exhibited only
2% low-grade serous mutations (Ziai and Hui, 2012). Con-
versely, in low-grade ovarian serous carcinoma patients, the
correlation between BRAF and KRAS has not yet been
explored. Additionally, unlike previous ﬁndings, one report
discussed the low frequency characterisation of KRAS and
BRAF mutations in advanced stage low-grade serous carcino-
mas (Wong et al., 2010). Recently, 20–40% of low-grade
serous carcinomas have been characterised with KRAS muta-
tions, while BRAF mutations are found in approximately 5%
of this subtype (Gershenson, 2013). In the literature, most of
the BRAF mutations have been identiﬁed using DNA-based
techniques; however, Bo¨smu¨ller et al. differentiated the BRAF
V600E mutation using mutation-speciﬁc monoclonal antibody
(VE1) speciﬁc for the BRAF V600E. This ability to immuno-
stain the BRAF V600E mutant protein in serous ovarian
tumour samples with low epithelial content demonstrates the
practical usefulness of mutation-speciﬁc recognition by an
antibody (VE1) (Bosmuller et al., 2013).6. Population based speciﬁcity of BRAF mutations in prostate
cancer
Prostate cancer, the most common cancer type in Western
Europe and USA, has variable incidence of BRAF and/or
KRAS mutations among different races (Ren et al., 2012;
Shen et al., 2010). Three reports have recorded BRAF muta-
tions in prostate carcinomas, and one of these showed no
BRAF mutations in the American and German populations.
However, 10.2% of prostate carcinomas have been identiﬁed
as having BRAF mutations in the Korean population (Cho
et al., 2006). In addition, 10% of prostate cancer cases have
been characterised as having an activating BRAF mutation
in the Asian population (Kollermann et al., 2010). This differ-
ence in BRAF mutation frequency has been characterised in
many different ethnic backgrounds. According to recent
evidence, a gain in the RAF gene copy number resulted in
the activation of the RAS/RAF/MEK/ERK pathway was
found to be the main contributing element in the regulation
of prostate cancer in a Chinese population (Ren et al., 2012).
However, in another report of Chinese patients, KRAS muta-
tions at codons 12 and 13 were found in prostate cancer
patients while no BRAF mutation was observed at codon
600 (Shen et al., 2010). Caucasian patients had results similar
to the Chinese patients, suggesting that BRAF mutations are
rarely found in prostate cancer and are not connected with
tumour progression. Nevertheless, recurrent gene fusions have
shown that the SLC45A3-BRAF and ESRP1-RAF1 fusions
drive the molecular events occurring in advanced prostate
and gastric cancers, as well as melanoma (Palanisamy et al.,
2010). Subsequently, Kollermann et al. have argued that the
emergence and the increased usage of BRAF-targetedtherapies may have limited efﬁcacy in treating prostate cancer
patients (Kollermann et al., 2010).
7. Lung cancer
In the United States, approximately 150,000 lives are lost to
lung cancer each year. The therapies that are used to treat lung
cancer only support the survival of 15% of patients for a per-
iod of 5 years (Naoki et al., 2002). According to the National
Cancer Institute of the NIH (www.cancer.gov/cancertopics/
types/lung), it is estimated that 159,260 deaths will occur from
lung cancer (both non-small cell and small cell) in 2014.
Although speciﬁc therapies have been developed to target the
molecular alterations that lead to cancer, new therapeutic ele-
ments are still being developed based on genome-wide screen-
ing for genetic alterations to reduce the cancer death rate
(Brose et al., 2002).
Molecular mechanisms underlying lung cancer involve the
KRAS, BRAF, c-erbB-2 and EML4-ALK, and inactivation of
tumour suppressor genes, including p16INK4a, and RASSF1.
Recent genomic studies have identiﬁed the genetic changes that
lead to activating mutations in the BRAF, HER2, and KRAS
genes in lung adenocarcinomas, and these mutations can be
used as potential therapeutic targets in clinical decision-mak-
ing (Cardarella and Johnson, 2013). BRAF mutations are
found in 4% of non-small cell lung cancers (NSCLCs), and
half of these mutations are non-V600E (Cardarella et al.,
2013). Several other reports documented the identiﬁcation of
BRAF mutations in both small-cell and non-small-cell lung
cancer pathogenesis. In one such report, two BRAF mutations,
one in exon 11 (G465V) and one in exon 15 (L596R), have
been observed in 127 primary lung adenocarcinoma specimens
(Naoki et al., 2002). In another report, K438Q (exon 11),
K438T (exon 11), and K600E (15 exon) mutations were found
to be essential for AKT phosphorylation at Thr439 (Brose
et al., 2002). However, in addition to the Thr439 residue,
two additional sites of AKT phosphorylation, Ser364 and
Ser428, were found to regulate this multistep mechanism.
Hence, the target speciﬁc therapies for V600E are inadequate
for immediate clinical use in lung cancer.
8. Colorectal cancer
Colorectal cancer (CRC) is one of the leading causes of cancer
morbidity and mortality, and is the third most common malig-
nant tumour in the western world (Yuan et al., 2013; Siegel
et al., 2013). Genetic aberrations in the form of chromosomal
abnormalities, genetic mutations, and epigenetic alterations
regulate the development of colorectal cancer, which is a mul-
tistep phenomenon involving several genes (KRAS, BRAF,
MEK, ERK and c-Fos) that mediate proliferation, differentia-
tion, apoptosis, and angiogenesis.
Hypermethylation of the MLH1 promoter region results in
the loss of MLH1 protein expression and microsatellite insta-
bility (MSI) (Simpkins et al., 1999); this mutation leads to
hereditary non-polyposis colorectal cancer (HNPCC), which
represents 3–6% of the total burden of colorectal cancer
(Bettstetter et al., 2007). The clinical associations of the com-
bined MSI/BRAF subgroups in colorectal cancer were investi-
gated as tumour molecular biomarkers for prognostic risk
stratiﬁcation (Lochhead et al., 2013). In addition, KRAS and
Table 1 BRAF variations characterised in NS, CFC and LEOPARD patients.
Amino acid variation Syndrome BRAF protein domain References
T241M NS Zinc ﬁnger (Phorbol-ester/DAG-type) Sarkozy et al. (2009)
T241R NS Zinc ﬁnger (Phorbol-ester/DAG-type) Sarkozy et al. (2009)
W531C NS Protein kinase Sarkozy et al. (2009)
L597V NS Protein kinase Sarkozy et al. (2009)
T241P CFC & LEOPARD Zinc ﬁnger (Phorbol-ester/DAG-type) Schulz et al. (2008) and Sarkozy et al.
(2009)
T244P CFC Zinc ﬁnger (Phorbol-ester/DAG-type) Schulz et al. (2008)
L245F CFC Zinc ﬁnger (Phorbol-ester/DAG-type) Sarkozy et al. (2009)
A246P CFC Zinc ﬁnger (Phorbol-ester/DAG-type) Niihori et al. (2006), Sarkozy et al.
(2009) and Schulz et al. (2008)
Q257R CFC Zinc ﬁnger (Phorbol-ester/DAG-type) Rodriguez-Viciana et al. (2006),
Niihori et al. (2006), Sarkozy et al.
(2009) and Schulz et al. (2008)
Q262K CFC Zinc ﬁnger (Phorbol-ester/DAG-type) Schulz et al. (2008)
E275K CFC Zinc ﬁnger (Phorbol-ester/DAG-type) Sarkozy et al. (2009)
S467A CFC Nucleotide binding (ATP) Rodriguez-Viciana et al. (2006)
F468S CFC Nucleotide binding (ATP) Rodriguez-Viciana et al. (2006) and
Schulz et al. (2008)
G469E CFC & colon cancer Nucleotide binding (ATP) Rodriguez-Viciana et al. (2006) and
Schulz et al. (2008)
L485F CFC Protein kinase Rodriguez-Viciana et al. (2006),
Niihori et al. (2006) and Sarkozy
et al. (2009)
K499E CFC Protein kinase Rodriguez-Viciana et al. (2006),
Niihori et al. (2006) and Schulz et al.
(2008)
K499N CFC Protein kinase Sarkozy et al. (2009) and Schulz et al.
(2008)
E501G CFC Protein kinase Rodriguez-Viciana et al. (2006) and
Niihori et al. (2006)
E501K CFC Protein kinase Rodriguez-Viciana et al. (2006),
Niihori et al. (2006) and Sarkozy
et al. (2009)
L525P CFC Protein kinase Sarkozy et al. (2009)
W531C NS Protein kinase Sarkozy et al. (2009)
N580D CFC Protein kinase Schulz et al. (2008)
N581D CFC Protein kinase Rodriguez-Viciana et al. (2006),
Niihori et al. (2006) and Schulz et al.
(2008)
F595L CFC & colon cancer Protein kinase Davies et al. (2002), Rodriguez-
Viciana et al. (2006), Sarkozy et al.
(2009) and Schulz et al. (2008)
G596V CFC Protein kinase Rodriguez-Viciana et al. (2006)
T599R CFC Protein kinase Sarkozy et al. (2009)
K601Q CFC Protein kinase Sarkozy et al. (2009)
D638E CFC Protein kinase Sarkozy et al. (2009)
Q709R CFC Protein kinase Sarkozy et al. (2009)
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in CRC patients with synchronous liver metastasis (Huang
et al., 2013; Umeda et al., 2013). Screening for both BRAF
mutations in codon 600 and KRAS mutations in codons 12,
13, and 61 are suggested as biomarkers to predict the efﬁcacy
of anti-epidermal growth factor receptor (EGFR) treatment
in colorectal cancer (Lewandowska et al., 2013). Additionally,
the accumulation of several genetic alterations, such as
T1796A (V599E), G1382T (R461I), T1385G (I462S),
G1388A (G463E) and A1798G (K600E), are more commonly
found in larger adenomas (<1 cm across) than in smaller
adenomas (Rajagopalan et al., 2002). However, a recent
report about genetic progression of BRAF(V600E)-basedtumourigenesis has provided a rationale for clinical evaluation
of MEK, PI3K, and BRAF-inhibitors in BRAF mutant CRC
(Rad et al., 2013; Popovici et al., 2012).
9. Developmental disorders: Noonan syndrome, cardio-facio-
cutaneous syndrome and LEOPARD syndrome
Distinctive facial dysmorphia, reduced growth, variable cogni-
tive deﬁcits, cardiac defects, skeletal and ectodermal anomalies
are overlapping features of three developmental disorders: NS,
LEOPARD (LS), and CFC syndromes. Genetic deregulation
of the BRAF gene (Table 1) is associated with the alteration
of the RAS–MAPK signal transduction pathway, resulting in
Clinical signiﬁcance of the BRAF gene 367the molecular lesions observed in NS, LS, and CFC patients
(Sarkozy et al., 2009; Schulz et al., 2008; Roberts et al., 2006).
Along with PTPN11 and RAF1, mutations in the BRAF
gene are also associated with a disorder complex termed
LEOPARD syndrome (LS-3). Mutations in these three genes
have been identiﬁed in 95% of LS-affected individuals
(Martinez-Quintana and Rodriguez-Gonzalez, 2012). A het-
erozygous de novo mutation (Thr241Pro) in the BRAF gene
was found in an LS patient, as reported by Sarkozy et al.
(2009). In vitro functional studies have identiﬁed that the
BRAF-T241P mutation results in increased activation of the
downstream MAPK pathway and is associated with
developmental syndromes (RASopathies) such as NS, LS, neu-
roﬁbromatosis 1 and capillary malformation-arteriovenous
malformation (Tidyman and Rauen, 2009). Furthermore,
Koudova et al. (2009) reported a LS patient with normal intel-
ligence, who was characterised with a novel alteration
(Leu245Phe) in the BRAF gene (Table 1). In addition to LS
and NS, the CFC syndrome has been diagnosed by mutations
in four genes––BRAF, KRAS, MAP2K1 and MAP2K2––that
regulate the Ras–MAPK cascade (Tidyman and Rauen,
2008; Siegel et al., 2011). The role of the KRAS mutations
has been identiﬁed in clinically diagnosed individuals with
NS and CFC syndrome (Rauen et al., 2010). Approximately
40% of the clinically diagnosed NS patients have been charac-
terised with mutations in the PTPN11 gene. The RAF1 gene,
which is located on chromosome 3p25.1, is also characterised
by missense mutations that account for 3–17% of NS individ-
uals (Tidyman and Rauen, 2008). However, no PTPN11 muta-
tion has been found in patients with CFC syndrome (Niihori
et al., 2006).
10. Noonan syndrome (NS) and Noonan-like syndrome (NLS)
Noonan syndrome (OMIM: 164757) is an autosomal domi-
nant developmental disorder characterised by facial dysmor-
phism including dolichocephaly, prominent forehead,
hypertelorism, and low-set ears, and cardiac defects (Sarkozy
et al., 2009), and is mostly associated with mutations in the
PTPN11, SOS1, BRAF and KRAS genes (Tartaglia et al.,
2001; Tidyman and Rauen, 2009; Gos et al., 2012; Kitsiou-
Tzeli et al., 2006). However, Noonan-like syndrome (NLS) is
comprised of Costello syndrome (CS; OMIM 218040), CFC
syndrome (OMIM: 115150), neuroﬁbromatosis type 1 (NF-1;
OMIM: 162200), and Legius syndrome (OMIM: 611431),
which are clinically associated with NS, and carries mutations
in the KRAS, HRAS, BRAF,MEK1, andMEK2 genes (Quaio
et al., 2013). Due to the overlapping clinical features and alter-
ations of the same molecular mechanisms in the RAS/MAPK
pathway (RASopathies), NS and NLS have been grouped
together in the neuro-cardio-facial-cutaneous syndrome family
(Malaquias et al., 2012). Postnatal short stature is one of the
cardinal signs of NS and NLS; however, the pathophysiologi-
cal mechanism of growth aberration remains unclear.
Noonan syndrome (NS) is one of the most common
dysmorphic syndromes and is described as having cardinal fea-
tures such as pulmonic stenosis (PS), a distinctive dysmorphic
facial appearance with hypertelorism, postnatally reduced
growth, ectodermal and haematologic anomalies, variable
cognitive deﬁcits and skeletal, and congenital heart defects
and hypertrophic cardiomyopathy (Tartaglia et al., 2011).Because it is a heterogeneous disorder, this Mendelian trait is
casually associated with nine genes (RAF1, BRAF, SOS1,
KRAS, NRAS, MEK1, PTPN11, SHOC2 and CBL), similar
to LEOPARD syndrome (Tartaglia et al., 2011). Approxi-
mately 40% of the clinically diagnosed NS individuals are
characterised with PTPN11 missense mutations (Tidyman
and Rauen, 2009, 2008). Similar to PTPN11, missense muta-
tions in the SOS1 gene are the second leading cause of NS
and account for 13% of individuals (Tidyman and Rauen,
2008). Ras-GEF is responsible for stimulating the conversion
of inactive Ras to its active form, and this conversion is dis-
rupted by mutations in the SOS1 gene, resulting in an increase
in the active Ras thereby leading to an increased Ras/MAPK
pathway signalling (Tidyman and Rauen, 2009). Similar to
SOS1, missense mutations in the RAF1 gene are responsible
for 3–17% of the NS individuals (Tidyman and Rauen,
2008). However, mutations in other genes, such as MEK1
and BRAF, account for <2% of the NS cases (Sarkozy
et al., 2009). In exon 13 and 15 of the BRAF gene, Sarkozy
et al. (2009) characterised Noonan syndrome-7 patients with
2 heterozygous de novo transversions––W531C (1593G-C)
and L597V (1789C-G) respectively. Moreover, in recent
reports, NS has frequently been associated with tumour and
haematological malignancies (Aoki and Matsubara, 2013;
Gremer et al., 2011).
11. Cardio-facio-cutaneous syndrome
Cardio-facio-cutaneous syndrome, which presents with
multiple congenital anomalies and mental retardation, was
ﬁrst reported in 1986 (Reynolds et al., 1986). However, the
phenotypic overlap between CFC syndrome and NS was
emphasised by Fryer in 1991 (Fryer et al., 1991). CFC shares
several phenotypic features with NS and Costello syndrome
(Niihori et al., 2006). The similarities between CFC and NS
can make the differentiation difﬁcult in infants; however, the
phenotypic features become more distinctive with the passage
of time.
CFC is caused by mutations in four identiﬁed genes that
encode proteins involved in the Ras–MAPK pathway, includ-
ing the BRAF, KRAS, MAP2K1 and MAP2K2 genes
(Tidyman and Rauen, 2008). In 2006, Niihori et al. compared
the BRAF-positive and KRAS-positive individuals with CFC
and identiﬁed the difference in manifestations––skin abnormal-
ities, including ichthyosis, hyperkeratosis, and hemangioma––
between the two groups (Niihori et al., 2006). However, the
role of the KRAS gene remains unclear as KRAS mutations
have been identiﬁed in individuals clinically diagnosed with
NS as well as CFC syndrome (Rauen et al., 2010). No
PTPN11 (Niihori et al., 2006) or HRAS mutations have been
detected in patients with CFC syndrome (Rodriguez-Viciana
et al., 2006). Heterogeneous missense mutations in the BRAF
gene are present in approximately 75% of CFC individuals
with CFC-1 (OMIM: 115150) Tidyman and Rauen, 2009.
The BRAF mutations that are associated with CFC syndrome
are found in exons 6, 11, 12, 13, 14, 15 and 16. The majority of
these mutations are found in exon 6 (41%) and exon 12 (21%).
The most common mutation that occurs in exon 6 is a missense
Q257R substitution (29% occurrence). In exons 12 and 11, the
E501G (12%) and G469E (6%) missense substitutions, respec-
tively, have been found in patients with CFC syndrome
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missense mutations in MAP2K1 (MEK1) and MAP2K2
(MEK2) are found in approximately 25% of CFC cases. The
MAP2K1 gene is located on chromosome 15q22.31 and
encodes the mitogen-activated protein kinase 1 (MEK1), while
the MAP2K2 gene is located on chromosome 19p13.3 and
encodes the protein MEK2 (Tidyman and Rauen, 2008). Both
isoforms have the ability to activate ERK1 and ERK2
(Tidyman and Rauen, 2009).
Although, Costello, Noonan and CFC syndromes have
overlapping phenotypic features, the HRAS gene is mutated
in Costello syndrome; this is in contrast to NS, which has
mutations in the PTPN11 and SOS1 genes, and CFC syn-
drome, which has mutations in the BRAF (75%), MAP2K1
and MAP2K2 (25%), and KRAS (<2%) genes. The overlap
in phenotypic features may be caused by the biochemical rela-
tionship of these mutated genes in each syndrome.
12. LEOPARD syndrome
The word LEOPARD is an acronym for a combination of
disorders with multiple lentigines (L), ECG abnormalities
(E), ocular hypertelorism (O), pulmonary stenosis (P), abnor-
malities of the genitalia (A), retardation in growth (R), and
deafness (D) (Gorlin et al., 1960). Although this syndrome
has multiple disorders, it is not considered to have a life
threatening diagnosis. Most of the people diagnosed with the
aforementioned manifestations live normal lives. However,
the patients with cardiac deformities have a profoundly high
risk of death due to obstructive cardiomyopathy and its
relevant pathologic severity towards the cardiovascular system
(Jozwiak et al., 1996; Bissler et al., 2013).
LEOPARD syndrome, a rare autosomal dominant multi-
system disorder, has been characterised with mutations in
PTPN11, RAF1, and BRAF genes. Approximately 90% of
all individuals with LEOPARD syndrome have a PTPN11
mutation. In the remaining 10%, a RAF1 mutation is most
common. In a small number of cases, the underlying genetic
cause is still unknown.
Sequence analysis of exons 6, 13, and 16 of the RAF1 gene
detects all reported missense mutations that are clinically
associated with LS (Allanson and Roberts, 1993; Pandit
et al., 2007). Additionally, sequence analysis of the RAF1
gene has indicated that no exon or whole-gene deletions or
duplications have been documented for LEOPARD syn-
drome, to-date (Gelb and Tartaglia, 1993). However, sequenc-
ing analysis of the BRAF gene has uncovered missense
mutations in all the coding exons in individuals with the
clinical features of LS (OMIM: 613707) Sarkozy et al.,
2009; Koudova et al., 2009.
LEOPARD syndrome is quite similar to NS but occurs
with a low frequency. Many features of LS show signiﬁcant
overlap with NS, including an autosomal dominant inheri-
tance, similar facial dysmorphisms and similar cardiac defects.
Both syndromes are caused by mutations in various genes
encoding members of the RAS–MAPK signalling cascade
and result in the deregulation of this pathway (Koudova
et al., 2009). In LS, PTPN11 mutations appear to inactivate
the protein function, while the protein remains activated in
NS. This suggests that different mechanisms underlie the two
related syndromes.13. Cancer in CFC and NS
Clinical manifestations of NS are similar to those of CFC and
LEOPARD syndromes. According to recent reports, NS,
LEOPARD and CFC patients have an increased risk of
tumour development (Fig. 3B) (Aoki and Matsubara, 2013;
Denayer et al., 2010), although no precise estimates are avail-
able yet (Hasle, 2009). Mutations in the Noonan-associated
genes (RAF1, KRAS, PTPN11 and SOS1) have also been
found in human tumours such as colon, pancreas, thyroid,
lung and melanomas (Denayer et al., 2010). The co-incidence
of NS-neuroﬁbromatosis with CFC and of rhabdomyosar-
coma with NS, with somatic mutations, has been described
in different reports in the literature (Hasle, 2009; Moschovi
et al., 2007; Khan et al., 1995). However, there is an increased
frequency of neuroﬁbromatosis type 1 (NF-1), which results in
the development of malignant schwannomas, phaeochromocy-
tomas, and acute lymphoblastic leukaemia, in NS patients
(Khan et al., 1995). First, a report about the association of Ser-
toli cell tumours and NS was put forth by Fryssira et al.
(2008). In this report, the development of solid tumours was
observed in patients diagnosed with Noonan syndrome. Pilo-
cytic astrocytomas (Pas), granular cell tumours and Sertoli
tumours in the testis are different types of tumours that have
been observed in NS patients (Fryssira et al., 2008). The
increased incidence of PAs (PA19, PA41 and PA42) with
hyperactivation of the RAS/RAF signalling is diagnosed with
clinical features of Neuroﬁbromatosis type 1 (NF1) syndrome
(Jones et al., 2008). In another published study, a very large
region of copy number-LOH (CN-LOH) proximal to the loca-
tion of the NF1 gene is proposed to affect the development of
multiple different tumour types, including low-grade gliomas.
Different reports have identiﬁed the duplication of the 7q34
region with HIPK2-BRAF and KIAA1549-BRAF gene fusion
products in low-grade paediatric astrocytomas (Sievert et al.,
2009). Moreover, FAM131B-BRAF gene fusion, and fusion
variants of BRAF and RAF1 genes have been characterised
in paediatric astrocytoma (Cin et al., 2011).
To explore the role of the aberrant RAS–MAPK signalling
in syndromic multiple giant cell lesions (MGCL) accompanied
by NS (Bertola et al., 2001; Lee et al., 2005), a cohort of 75
NS patients was identiﬁed as carrying BRAF mutations
(Neumann et al., 2009). The occurrence of MGCL in NS
and CFC patients with various underlying genetic alterations
corroborates the deregulation of the RAS–MAPK pathway,
which causes these patients to be predisposed to giant cell
lesion (Neumann et al., 2009).
Tumour screening in CFC patients has been given little
attention until the molecular analyses become available
(Aoki and Matsubara, 2013). Both germline and somatic
mutations in the BRAF and KRAS genes associated with
CFC syndrome have been identiﬁed in hepatoblastoma (Al-
Rahawan et al., 2007), non-Hodgkin lymphoma (Ohtake
et al., 2011), juvenile myelomonocytic leukaemia-like (JMML)
Schubbert et al., 2006, malignant melanoma (Makita et al.,
2007), and cancers of the colon, thyroid and lung (Fig. 4)
(Makita et al., 2007). However, JMML myeloproliferative dis-
orders have also been characterised as containing PTPN11
mutations, similar to NS (Hasle, 2009). Somatic BRAF muta-
tions are substantially documented in haematological malig-
nancies but with low frequency. The recent identiﬁcation of
Figure 4 Genes––KRAS, BRAF, PTPN11 and SOS1––characterised in both human cancers and RAS/MAPK syndromes (CFC &
Noonan).
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matological malignancies suggests that the BRAF gene has a
role beyond solid tumours (Al-Rahawan et al., 2007).
14. Conclusion and future prospects
Mutations in BRAF expression have been important in under-
standing the roles that BRAF and other members of the
RAS/RAF cascade play in disease progression, and detail
mechanistic study can help to approach effective BRAF
inhibitors for cancer diseases. However, growing concerns
over drug resistance to molecular targeted therapies
(Chakraborty et al., 2013), including BRAF and MEK inhib-
itors, have stimulated investigators to uncover additional
molecular targets for the treatment of cancers as well as for
RASopathies, in the hope of providing personalised medicine.
The goal of personalised medicine is to explore different tech-
niques associated with cancer therapy and the management of
various malignancies in RASopathies. Although the regula-
tion and inhibition of the RAS/MAPK pathway have been
widely studied in cancer research, the natural history and
predisposition of individuals with NS, CFC and LEOPARD
syndromes, characterised as a result of disruption of the
RAS/MAPK cascade, have not been understood. Addition-
ally, the molecular phenomena of the RAS/MAPK cascade
underlying overlapping features and varied degrees of
penetrance in NS, CFC and LEOPARD (RAS/MAPK)
syndromes are largely unknown.
In a mouse model, inhibition of mTOR, which regulates
mRNA translation and ribosome synthesis, intriguingly indi-
cated the reverse heart defects for NS multiple lentigines.
Additionally, HMG-CoA reductase inhibitors and MEK
inhibitors ameliorated the phenotype of the NS and NF-1
mouse models (mutations in SOS1 and RAF1) (Gelb and
Tartaglia, 2011; Bauer and Stratakis, 2005; Wu et al., 2011).
Such ﬁndings suggest that the complete manipulation of
RAS/MAPK activity can help to correct the aberrant activa-
tion of the RAS-RAF signalling that is responsible for variable
clinical phenotypes in the form of RAS–MAPK syndromes,
and associated cancer risks.
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